<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000674058"><TermName>navitoclax</TermName><TermPronunciation>(na-VIH-toh-klax)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying. It is a type of Bcl-2 family inhibitor. Also called ABT-263.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000727554" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;navitoclax&quot;" language="en" id="_3"/><MediaLink ref="CDR0000727553" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;navitoclax&quot;" language="es" id="_4"/><SpanishTermName>navitoclax</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de los linfomas y otros tipos de cáncer. Bloquea algunas de las enzimas que impiden que las células cancerosas mueran. Es un tipo de inhibidor de la familia Bcl-2. También se llama ABT-263.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-05-19</DateFirstPublished></GlossaryTerm>
